These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21072518)

  • 1. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
    Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
    Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
    J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
    Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
    Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
    Di Renzo N; Brugiatelli M; Montanini A; Vigliotti ML; Cervetti G; Liberati AM; Luminari S; Spedini P; Giglio G; Federico M
    Leuk Lymphoma; 2006 Mar; 47(3):473-9. PubMed ID: 16396771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
    Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
    Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin lymphoma after autologous hematopoietic stem cell transplantation.
    Ozkaynak MF; Jayabose S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):107-13. PubMed ID: 15160509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
    Naqi N; Ahmad S; Shah I; Khattak J
    J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma.
    Marr K; Ronsley R; Nadel H; Douglas K; Gershony S; Strahlendorf C; Davis JH; Deyell RJ
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28167. PubMed ID: 31925920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
    Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
    Arai S; Letsinger R; Wong RM; Johnston LJ; Laport GG; Lowsky R; Miklos DB; Shizuru JA; Weng WK; Lavori PW; Blume KG; Negrin RS; Horning SJ
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1145-54. PubMed ID: 20197102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.
    Pasricha SR; Grigg A; Catalano J; Leahy M; Underhill C; Arthur C; D'Rozario J; Lowenthal R; Reed K; Spencer A
    Cancer; 2008 Dec; 113(11):3192-8. PubMed ID: 18932253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
    Cole PD; Schwartz CL; Drachtman RA; de Alarcon PA; Chen L; Trippett TM
    J Clin Oncol; 2009 Mar; 27(9):1456-61. PubMed ID: 19224841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children.
    Jaffray M; Buchbinder N; Lutun A; Schneider P; Piquenot JM; Vannier JP
    Ann Hematol; 2015 Aug; 94(8):1401-6. PubMed ID: 25862234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
    Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
    Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
    Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
    Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
    Balzarotti M; Brusamolino E; Angelucci E; Carella AM; Vitolo U; Russo E; Congiu A; Gotti M; Massidda S; Botto B; Annechini G; Spina M; Re A; Zilioli VR; Merli F; Salvi F; Stelitano C; Bonfichi M; Rodari M; Murru R; Magagnoli M; Anastasia A; Mazza R; Giordano L; Santoro A
    Leuk Lymphoma; 2016 Oct; 57(10):2375-81. PubMed ID: 26879066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
    Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
    Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
    Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R
    Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.
    Swoboda R; Giebel S; Knopińska-Posłuszny W; Chmielowska E; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Kulikowski W; Taszner M; Mendrek W; Najda J; Czerw T; Olszewska-Szopa M; Czyż A; Giza A; Spychałowicz W; Subocz E; Szwedyk P; Krzywon A; Wilk A; Zaucha JM
    Ann Hematol; 2021 Jul; 100(7):1755-1767. PubMed ID: 33625572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.